Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
J Periodontal Res ; 45(5): 602-11, 2010 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-20546115

RESUMO

BACKGROUND AND OBJECTIVE: Amelogenins are hydrophobic proteins that are the major component of developing enamel. Enamel matrix derivative has been used for periodontal regeneration. Bone sialoprotein is an early phenotypic marker of osteoblast differentiation. In this study, we examined the ability of porcine amelogenins to regulate bone sialoprotein transcription. MATERIAL AND METHODS: To determine the molecular basis of the transcriptional regulation of the bone sialoprotein gene by amelogenins, we conducted northern hybridization, transient transfection analyses and gel mobility shift assays using the osteoblast-like ROS 17/2.8 cells. RESULTS: Amelogenins (100 ng/mL) up-regulated bone sialoprotein mRNA at 3 h, with maximal mRNA expression occurring at 12 h (25 and 20 kDa) and 6 h (13 and 6 kDa). Amelogenins (100 ng/mL, 12 h) increased luciferase activities in pLUC3 (nucleotides -116 to +60), and 6 kDa amelogenin up-regulated pLUC4 (nucleotides -425 to +60) activity. The tyrosine kinase inhibitor inhibited amelogenin-induced luciferase activities, whereas the protein kinase A inhibitor abolished 25 kDa amelogenin-induced bone sialoprotein transcription. The effects of amelogenins were abrogated by 2-bp mutations in the fibroblast growth factor 2 response element (FRE). Gel-shift assays with radiolabeled FRE, homeodomain-protein binding site (HOX) and transforming growth factor-beta1 activation element (TAE) double-strand oligonucleotides revealed increased binding of nuclear proteins from amelogenin-stimulated ROS 17/2.8 cells at 3 h (25 and 13 kDa) and 6 h (20 and 6 kDa). CONCLUSION: These results demonstrate that porcine 25 kDa amelogenin and its proteolytic derivatives stimulate bone sialoprotein transcription by targeting FRE, HOX and TAE in the bone sialoprotein gene promoter, and that full-length amelogenin and amelogenin cleavage products are able to regulate bone sialoprotein transcription via different signaling pathways.


Assuntos
Amelogenina/farmacologia , Sialoproteína de Ligação à Integrina/biossíntese , Regiões Promotoras Genéticas/efeitos dos fármacos , Transdução de Sinais/efeitos dos fármacos , Transcrição Gênica/efeitos dos fármacos , Amelogenina/metabolismo , Animais , Sítios de Ligação , Northern Blotting , Linhagem Celular , Sondas de DNA , Ensaio de Desvio de Mobilidade Eletroforética , Elementos Facilitadores Genéticos/efeitos dos fármacos , Fator 2 de Crescimento de Fibroblastos/genética , Regulação da Expressão Gênica no Desenvolvimento , Proteínas de Homeodomínio/genética , Sialoproteína de Ligação à Integrina/genética , Luciferases/metabolismo , Mutagênese Sítio-Dirigida , Osteoblastos/efeitos dos fármacos , Osteoblastos/metabolismo , Ratos , Elementos de Resposta/efeitos dos fármacos , Suínos , Transfecção , Fator de Crescimento Transformador beta1/genética , Regulação para Cima
2.
J Periodontal Res ; 44(5): 657-63, 2009 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-19054295

RESUMO

BACKGROUND AND OBJECTIVE: Tobacco smoking is a risk factor for periodontitis and osteoporosis. Nicotine is a major component of tobacco, and has been reported to inhibit proliferation and differentiation of osteoblasts. Bone sialoprotein (BSP) is a mineralized tissue-specific protein expressed by differentiated osteoblasts that appears to function in the initial mineralization of bone. The purpose of this study was to determine the effects of nicotine on bone metabolism. MATERIAL AND METHODS: We used rat osteobast-like UMR106 and ROS 17/2.8 cells and rat stromal bone marrow RBMC-D8 cells. To determine the molecular basis of the transcriptional regulation of the BSP gene by nicotine, we conducted Northern hybridization, transient transfection analyses with chimeric constructs of the BSP gene promoter linked to a luciferase reporter gene and gel mobility shift assays. RESULTS: Nicotine (250 microg/mL) decreased the BSP mRNA levels at 12 and 24 h in UMR106 and ROS 17/2.8 cells. From transient transfection assays using various sized BSP promoter-luciferase constructs, nicotine decreased the luciferase activities of the construct, including the promoter sequence nucleotides -116 to +60, in UMR106 and RBMC-D8 cells. Nicotine decreased the nuclear protein binding to the cAMP response element (CRE), fibroblast growth factor 2 response element (FRE) and homeodomain protein-binding site (HOX) at 12 and 24 h. CONCLUSION: This study indicates that nicotine suppresses BSP transcription mediated through CRE, FRE and HOX elements in the proximal promoter of the rat BSP gene.


Assuntos
Nicotina/farmacologia , Agonistas Nicotínicos/farmacologia , Sialoglicoproteínas/efeitos dos fármacos , Animais , Northern Blotting , Células da Medula Óssea/efeitos dos fármacos , Linhagem Celular , Quimera/genética , Proteína de Ligação ao Elemento de Resposta ao AMP Cíclico/efeitos dos fármacos , Ensaio de Desvio de Mobilidade Eletroforética , Fator 2 de Crescimento de Fibroblastos/genética , Genes Reporter/genética , Proteínas de Homeodomínio/efeitos dos fármacos , Sialoproteína de Ligação à Integrina , Luciferases/genética , Proteínas Nucleares/efeitos dos fármacos , Osteoblastos/efeitos dos fármacos , Regiões Promotoras Genéticas/genética , RNA Mensageiro/efeitos dos fármacos , RNA Mensageiro/genética , Ratos , Elementos de Resposta/efeitos dos fármacos , Sialoglicoproteínas/genética , Células Estromais/efeitos dos fármacos , Fatores de Tempo , Transcrição Gênica/efeitos dos fármacos , Transfecção
3.
Br J Ophthalmol ; 74(8): 472-6, 1990 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-2390522

RESUMO

A study was made of parameters of congenital nystagmus which responded to auditory biofeedback treatment. The parameters studied included foveation time, amplitude, and frequency. The patient's right retina was observed with an infrared television fundus camera, and the fundus image was recorded on video tape. The position of the eye during nystagmus, observed via the fundus camera and recorded on video, was analysed at every 1/60 second intervals. The displacement in degrees between the fixation target, projected on to the retina, and the foveola was measured for each interval. Using biofeedback, the subjects could voluntarily suppress nystagmus and prolong foveation time. A damping of the nystagmus amplitude, intensity, and frequency was observed. On the average the intensity decreased by about 40%, and the foveation time was prolonged by about 190%. After completion of the training all the patients reported a subjective improvement in their vision when suppressing their nystagmus. Possibly biofeedback training acts to reduce the nystagmus and extend foveation time, thereby improving the ability to fixate.


Assuntos
Biorretroalimentação Psicológica , Nistagmo Patológico/congênito , Adolescente , Adulto , Criança , Movimentos Oculares , Feminino , Humanos , Masculino , Nistagmo Patológico/fisiopatologia , Nistagmo Patológico/terapia
4.
Nippon Ganka Gakkai Zasshi ; 97(8): 967-74, 1993 Aug.
Artigo em Japonês | MEDLINE | ID: mdl-8368186

RESUMO

Lipoprotein (a) (Lp(a)) has been considered an independent risk factor for arteriosclerotic disease and its role in retinal vascular changes was studied in this report. The study was made on 160 patients of age 54 and above. They were divided into four groups depending upon their clinical background with or without the presence of diabetes mellitus (DM) and cerebral infarction (CI). The retinal vascular status of the patients was studied by ophthalmoscopic examination and the findings were graded according to Scheie's classification. We found that all the patients with retinal arterial hypertension and arteriosclerosis had a significant by high level of serum Lp (a). Similarly, serum Lp (a) level was higher in the patients with DM and CI than in the control subjects. These findings suggested that Lp (a) might influence the pathological changes of senile retinal arterioles. Moreover, we found a positive linear correlation between Lp (a) and plasminogen in patients with CI.


Assuntos
Arteriosclerose/sangue , Lipoproteína(a)/sangue , Artéria Retiniana/patologia , Idoso , Idoso de 80 Anos ou mais , Arteríolas , Arteriosclerose/patologia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Doenças Retinianas/sangue , Doenças Retinianas/patologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA